基本信息
浏览量:207
职业迁徙
个人简介
As a gastrointestinal oncologist with a primary interest in translational oncology research, my work focuses on targeted therapies directed against specific mutations commonly found in human cancers, with a focus on BRAF and KRAS mutant gastrointestinal cancers. My work explores the hypothesis that the optimal therapy for individual tumors may vary widely based on the genetic alterations present, and that prior knowledge of these genetic changes and an understanding of the signaling pathways involved will allow selection of an optimal targeted agent or combination of agents capable of inhibiting the critical survival signals within a given tumor.
My work on BRAF mutant cancers has focused on determinants of resistance to BRAF and MEK inhibitors. We have identified BRAF amplification as a potential cause of acquired and de novo resistance in BRAF mutant colorectal cancers (Science Signaling, 2010), and have shown that combined BRAF and MEK inhibition can overcome resistance. We have also demonstrated that combined BRAF and MEK inhibition leads to increased efficacy in treatment-naïve BRAF mutant colorectal cancer models, leading to the development of a clinical trial assessing combined BRAF and MEK inhibition in patients with BRAF mutant colorectal (ASCO Abstract, 2012; ASCO Abstract, 2013). Additionally, we have found that EGFR-mediated reactivation of MAPK signaling contributes to the relative insensitivity of BRAF mutant colorectal cancers to BRAF inhibition, compared to BRAF mutant melanomas, and that combined BRAF and EGFR inhibition can overcome resistance, leading to tumor regressions in BRAF mutant colorectal xenografts (Cancer Discovery, 2012). Clinical trials based on this concept are currently enrolling patients. We are also focused on identifying additional causes of de novo and acquired resistance in BRAF mutant cancers using a combination of preclinical models and patient tumor specimens. (Cancer Discovery, 2015). Simultaneously, we are developing biomarkers to predict response to therapy (Cancer Discovery, 2011), including real-time pharmacodynamic assessment of signaling changes in on-treatment patient tumor biopsies (Science Translational Medicine, 2013), and combination therapy strategies to overcome resistance.
In KRAS mutant cancers, we have demonstrated the effectiveness of combination therapies involving inhibition of the PI3K and MEK pathways in mouse models of KRAS mutant cancers (J Clinical Investigation, 2011) and have evaluated the role of STAT3 in KRAS-induced pancreatic tumorigenesis (Cancer Research, 2011). Our current work focuses on identifying new combination therapy approaches to KRAS mutant cancers in an effort to identify novel target pathways. Recently, we identified combined targeting of BCL-XL and MEK as a promising therapeutic strategy that leads to dramatic tumor regressions in KRAS mutant xenografts and in KRAS-driven genetically-engineered mouse tumor models (Cancer Cell, 2013). A clinical trial based on this concept and funded by NCI/CTEP is currently enrolling patients, for which I am principal investigator. By identifying and understanding key mechanisms of response and resistance to targeted therapies, we hope to devise and validate potential clinical strategies for BRAF and KRAS mutant cancers.
My work on BRAF mutant cancers has focused on determinants of resistance to BRAF and MEK inhibitors. We have identified BRAF amplification as a potential cause of acquired and de novo resistance in BRAF mutant colorectal cancers (Science Signaling, 2010), and have shown that combined BRAF and MEK inhibition can overcome resistance. We have also demonstrated that combined BRAF and MEK inhibition leads to increased efficacy in treatment-naïve BRAF mutant colorectal cancer models, leading to the development of a clinical trial assessing combined BRAF and MEK inhibition in patients with BRAF mutant colorectal (ASCO Abstract, 2012; ASCO Abstract, 2013). Additionally, we have found that EGFR-mediated reactivation of MAPK signaling contributes to the relative insensitivity of BRAF mutant colorectal cancers to BRAF inhibition, compared to BRAF mutant melanomas, and that combined BRAF and EGFR inhibition can overcome resistance, leading to tumor regressions in BRAF mutant colorectal xenografts (Cancer Discovery, 2012). Clinical trials based on this concept are currently enrolling patients. We are also focused on identifying additional causes of de novo and acquired resistance in BRAF mutant cancers using a combination of preclinical models and patient tumor specimens. (Cancer Discovery, 2015). Simultaneously, we are developing biomarkers to predict response to therapy (Cancer Discovery, 2011), including real-time pharmacodynamic assessment of signaling changes in on-treatment patient tumor biopsies (Science Translational Medicine, 2013), and combination therapy strategies to overcome resistance.
In KRAS mutant cancers, we have demonstrated the effectiveness of combination therapies involving inhibition of the PI3K and MEK pathways in mouse models of KRAS mutant cancers (J Clinical Investigation, 2011) and have evaluated the role of STAT3 in KRAS-induced pancreatic tumorigenesis (Cancer Research, 2011). Our current work focuses on identifying new combination therapy approaches to KRAS mutant cancers in an effort to identify novel target pathways. Recently, we identified combined targeting of BCL-XL and MEK as a promising therapeutic strategy that leads to dramatic tumor regressions in KRAS mutant xenografts and in KRAS-driven genetically-engineered mouse tumor models (Cancer Cell, 2013). A clinical trial based on this concept and funded by NCI/CTEP is currently enrolling patients, for which I am principal investigator. By identifying and understanding key mechanisms of response and resistance to targeted therapies, we hope to devise and validate potential clinical strategies for BRAF and KRAS mutant cancers.
研究兴趣
论文共 243 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Ferran Fece de la Cruz,Andreas Varkaris,Elizabeth E. Martin, Bryanna L. Norden, Nicholas Chevalier, Allison M. Kehlmann,Ignaty Leshchiner,Haley Barnes, Sara Ehnstrom, Parasvi Patel, Janice S. Kim,Haley Ellis,
Cancer Researchno. 7_Supplement (2024)
Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz,Kevin S Kapner, Michael H Rosenthal, Bryanna L Norden, Haley Barnes, Sara Ehnstrom, Alvin A Morales-Giron,Lauren K Brais, Christopher T Lemke, Andrew J Aguirre,
Cancer discovery (2024)
Oluwadara Coker,Alexey Sorokin, Neal Akhave, Kelsey Pan, Fengqin Gao,Zhensheng Liu,Preeti Kanikarla, HeyMin Lee,Oscar Villarreal,Jumanah Alshenaifi, Giulia Maddalena, Alaa Mohamed,
Cancer Researchno. 6_Supplement (2024): 1937-1937
Hongcheng Yao,Vjola Jorgji, Alexander L. Tang,David Lieb,Sherry X. Chao, Daniel J. Stein,Maxwell Spurrell, Liad Elmelech, Jun Tian,Moshe Sade-Feldman,Karin Pelka,Ryan B. Corcoran,
Cancer Researchno. 6_Supplement (2024): 6555-6555
Andreas Varkaris,Ferran Fece de la Cruz,Elizabeth E. Martin, Bryanna L. Norden, Nicholas Chevalier, Allison M. Kehlmann,Ignaty Leshchiner,Haley Barnes, Sara Ehnstrom, Anastasia-Maria Stavridi,Xin Yuan, Janice S. Kim,
Rachel Occhiogrosso Abelman,Haley Barnes,Arielle J. Medford, Annika Putur,Bogang Wu,Caroline Weipert,Geoffrey Fell,Laura M. Spring,Seth A. Wander,Beverly Moy,Andreas Varkaris,Dejan Juric,
Cancer Researchno. 6_Supplement (2024): 3888-3888
Ryan B Corcoran,Khanh T Do,Jeong E Kim,James M Cleary,Aparna R Parikh,Oladapo O Yeku,Niya Xiong,Colin D Weekes,Jennifer Veneris, Leanne G Ahronian,Gianluca Mauri, Jun Tian,
Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Qibiao Wu,Haley Ellis,Giulia Siravegna, Alexa G Michel, Bryanna L Norden,Ferran Fece de la Cruz, Eranga Roshan Balasooriya,Yuanli Zhen, Vanessa S Silveira, Jianwe Che,Ryan B Corcoran,Nabeel Bardeesy
Clinical cancer research : an official journal of the American Association for Cancer Researchno. 1 (2024): 198-208
Parasvi S. Patel, Jun Tian,Ferran Fece de la Cruz, Jacquelyn Curtis, Apekshya Panda,Tomonori Oka,Shadmehr Demehri,Moshe Sade-Feldman, Scott Koptez,Ryan B. Corcoran
Cancer Researchno. 7_Supplement (2024)
Eranga R Balasooriya,Qibiao Wu,Haley Ellis,Yuanli Zhen, Bryanna L Norden,Ryan B Corcoran, Adithi Mohan,Eric Martin,Aleksandra Franovic,John Tyhonas, Matthew Lardy, Kathryn B Grandinetti,
Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn